GlaxoSmithKline plc’s PD-1 blocking antibody, Jemperli (dostarlimab-gxly), has been approved for a second indication in the US, the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. This is a broader indication than the product’s first license for dMMR endometrial cancer, and marks the company’s continued drive to again become a major player in the cancer field.
GSK Grows Immuno-Oncology Credentials With New Dostarlimab Indication
Tumor-Agnostic Indication Approved In The US
GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.
More from New Products
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.